Therefore, while the JACAL study had only included EGFR-mutated cases and did not specifically consider older patients, we believe that osimertinib may provide good outcomes among older patients with EGFR-mutated (T790M) NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.